GENESIS Ventures

Renalyse, operating under the registered trade name of CreatSens Health S.L., is a biotechnology company dedicated to the development of innovative medical platforms. The company specializes in the creation of point-of-care decentralized diagnostic devices that facilitate the analysis of critical biochemical parameters in blood. Its technology employs a paper sensor capable of providing results for significant biomarkers, such as creatinine and potassium, which are vital for the monitoring and management of chronic kidney disease. By enabling decentralized monitoring, Renalyse's devices allow for early prediction and detection of acute conditions, empowering patients to manage their health from the comfort of their homes.

Corify Care SL is a medical technology company based in Madrid, Spain, focused on advancing the treatment of cardiac arrhythmias, particularly atrial fibrillation. Founded in 2019, the company has developed ACORYS, a non-invasive electrocardiographic imaging device that allows healthcare professionals to visualize the electrical activity of the heart without the need for invasive catheters or complex imaging techniques like MRI or CT scans. This innovative device addresses the limitations of existing solutions by providing real-time mapping of cardiac arrhythmias, which can significantly enhance the clinical management of atrial fibrillation. Corify Care's technology aims to improve treatment outcomes for millions of patients in Europe, enabling effective diagnosis and personalized care during routine cardiology visits.

ABLE Human Motion is a Barcelona-based medical device start-up founded in 2018, focused on developing robotic exoskeletons to enhance mobility for individuals with disabilities. The company’s flagship product, the ABLE Exoskeleton, is a lightweight and user-friendly wearable device designed to assist paraplegic individuals in standing, walking, and sitting down. This innovative technology incorporates a motor and gearbox that mimic muscle function, along with inertial sensors that detect the user's intentions. By enabling greater mobility and independence, the ABLE Exoskeleton aims to improve the quality of life for its users while also serving as a rehabilitation tool for clinicians, enhancing the efficiency of therapy and promoting daily ambulation within the community.

Mowoot is a company that specializes in developing wearable medical devices aimed at improving the quality of life for individuals suffering from chronic constipation. Founded in 2014 and based in Barcelona, Spain, Mowoot offers a non-pharmacological and non-invasive solution that simulates a manual abdominal massage performed by healthcare professionals. Utilizing advanced pneumatic technology, its device provides automatic colon-specific massages to stimulate intestinal transit, thereby helping to treat and prevent chronic slow transit constipation without the need for colon cleansing supplements, enemas, or laxatives. Mowoot emerged from the MOEBIO dHEALTH program, drawing inspiration from concepts in design and business innovation.

Quality Pharma specializes in developing AI-powered medication evaluation tools, notably its proprietary QS System® (Quantum Satis). This software employs algorithm-driven analysis to identify potential adverse drug events in patients taking multiple medications (polypharmacy), flagging issues such as inappropriate drugs, drug duplication, interactions, and undertreatment. The system offers modules for analysis, monitoring, and evaluation, serving healthcare professionals and empowering individuals with a user-friendly interactive version. Its primary goal is to enhance elderly patient health by optimizing medication use and preventing drug-related problems.

NeuroHeal is a spinout from the Institut of Neurosciences from the Autonomous University of Barcelona.

ADmit Therapeutics, S.L. is a biotechnology company based in Begues, Spain, focused on developing diagnostic tests for the early detection of Alzheimer’s disease. Founded in 2017, the company utilizes epigenetic analysis of blood samples to identify a series of mitochondrial biomarkers, which are unrelated to traditional markers such as ß-amyloid or tau. By employing next-generation sequencing to analyze methylcytosines in mitochondrial DNA, ADmit Therapeutics provides medical practitioners with a simplified method for detecting early-stage Alzheimer’s disease. This innovative approach not only aids in diagnosis but also supports pharmaceutical companies in the accelerated identification of potential curative drugs.